Cymabay Therapeu Stock Beta
| CBAYDelisted Stock | USD 11.83 0.27 2.34% |
Cymabay Therapeu fundamentals help investors to digest information that contributes to Cymabay Therapeu's financial success or failures. It also enables traders to predict the movement of Cymabay Stock. The fundamental analysis module provides a way to measure Cymabay Therapeu's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cymabay Therapeu stock.
Cymabay |
Cymabay Therapeu Company Beta Analysis
Cymabay Therapeu's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Cymabay Therapeu Beta | 0.32 |
Most of Cymabay Therapeu's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cymabay Therapeu is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Cymabay Therapeu has a Beta of 0.32. This is 62.79% lower than that of the Pharmaceuticals sector and 76.98% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Cymabay Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cymabay Therapeu's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cymabay Therapeu could also be used in its relative valuation, which is a method of valuing Cymabay Therapeu by comparing valuation metrics of similar companies.Cymabay Therapeu is currently under evaluation in beta category among its peers.
As returns on the market increase, Cymabay Therapeu's returns are expected to increase less than the market. However, during the bear market, the loss of holding Cymabay Therapeu is expected to be smaller as well.
Cymabay Fundamentals
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (745.58) % | |||
| Current Valuation | 3.45 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 0.51 % | |||
| Shares Owned By Institutions | 99.49 % | |||
| Number Of Shares Shorted | 5.85 M | |||
| Price To Earning | (8.62) X | |||
| Price To Book | 12.76 X | |||
| Price To Sales | 119.98 X | |||
| Revenue | 31.07 M | |||
| Gross Profit | (41.63 M) | |||
| EBITDA | (101 M) | |||
| Net Income | (105.37 M) | |||
| Cash And Equivalents | 153.42 M | |||
| Cash Per Share | 1.81 X | |||
| Total Debt | 114.49 M | |||
| Debt To Equity | 1.45 % | |||
| Current Ratio | 12.20 X | |||
| Book Value Per Share | 2.57 X | |||
| Cash Flow From Operations | (72.53 M) | |||
| Short Ratio | 0.84 X | |||
| Earnings Per Share | (0.99) X | |||
| Target Price | 32.5 | |||
| Number Of Employees | 101 | |||
| Beta | 0.32 | |||
| Market Capitalization | 3.73 B | |||
| Total Asset | 434.69 M | |||
| Retained Earnings | (978.23 M) | |||
| Working Capital | 366.96 M | |||
| Current Asset | 42.79 M | |||
| Current Liabilities | 6.15 M | |||
| Z Score | 16.7 | |||
| Net Asset | 434.69 M |
About Cymabay Therapeu Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cymabay Therapeu's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cymabay Therapeu using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cymabay Therapeu based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |